Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma

by Moore, N.F, Azarova, A.M, Bhatnagar, N, Ross, K.N, Drake, L.E, Frumm, S, Liu, Q.S, Christie, A.L, Sanda, T, Chesler, L, Kung, A.L, Gray, N.S, Stegmaier, K, George, R.E
Published 2020